Biological switching
The medicines regulator MHRA states that NHS providers must consult with existing patients before switching them to a different biologic brand. This includes after patent expiry of the original reference product when biosimilar alternatives become available.
Shared decision-making
The NHS implements switching by contacting each patient to explain why moving to a different biologic brand is being planned and what it means for patient care. Homecare providers may contact patients on behalf of the NHS. Patients are offered a call or meeting with a clinician or another healthcare professional familiar with their condition to discuss their circumstances. Medicines UK supports this patient engagement and consultation before switching brands, as it is vital to protect the principle of shared decision-making between patient and prescriber.
If a patient subsequently wants to be switched back to their previous brand because of a clinical or treatment concern, then this should be discussed between the patient and the clinician. If both parties agree that there would be a genuine clinical benefit in returning to a previously prescribed brand, then the patient should return to it.